MHS552
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
September 28, 2023
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P1 | N=8 | Terminated | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2024 ➔ Jun 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Aug 2024 ➔ Jun 2023; Sponsor Decision
Trial completion date • Trial primary completion date • Trial termination • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
August 01, 2023
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P1 | N=8 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=28 ➔ 8
Enrollment change • Enrollment closed • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
April 07, 2023
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Novartis Pharmaceuticals | N=28 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
November 15, 2022
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P1 | N=28 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: May 2024 ➔ Aug 2024 | Trial primary completion date: May 2024 ➔ Aug 2024
Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
September 29, 2022
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=28 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2024 ➔ Apr 2025 | Initiation date: Oct 2022 ➔ Feb 2023 | Trial primary completion date: Dec 2024 ➔ Apr 2025
Trial completion date • Trial initiation date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
August 24, 2022
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=28 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2024 ➔ Dec 2024 | Initiation date: Jul 2022 ➔ Oct 2022 | Trial primary completion date: May 2024 ➔ Dec 2024
Trial completion date • Trial initiation date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
June 01, 2022
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=28 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Mar 2024 ➔ Sep 2024
Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
March 17, 2022
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P1 | N=28 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
March 09, 2022
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
(clinicaltrials.gov)
- P1 | N=28 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
January 24, 2022
Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)
(clinicaltrials.gov)
- P1; N=28; Not yet recruiting; Sponsor: Novartis Pharmaceuticals
New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 10
Of
10
Go to page
1